Results 231 to 240 of about 1,448,909 (408)

Effects of hypoxia and glutathione depletion on hemoglobin- and myoglobin-mediated oxidative stress toward endothelium1The opinions and assertions contained herein are the scientific views of the authors and are not to be construed as policy of the United States Food and Drug Administration or the United States Army.1

, 2000
Felice D’Agnillo, Francine Wood, Carlos Porras, Victor W. Macdonald, Abdu I. Alayash   +4 more
openalex   +1 more source

A view from the field on food and drug administration regulation: report of a 2002 survey of U.S. fertility clinics [PDF]

, 2003
Mark S. Frankel, Parisa Morris
openalex   +1 more source

Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology.

Journal of Pharmacy and Science, 2019
Manuela Grimstein, Yuching Yang, Xinyuan Zhang, J. Grillo, Shiew-Mei Huang, I. Zineh, Yaning Wang   +6 more
semanticscholar   +1 more source

Endocytic Programming via Porous Silicon Nanoparticles Enhances TLR4 Nanoagonist Potency for Macrophage‐Mediated Immunotherapy

Advanced Functional Materials, EarlyView.
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang, Huiying Li, Shuodan Huang, Linxuan Zhang, Yan Gao, Ruoran Wang, Xiaoyu Wang, Hélder A. Santos, Zhenyu Yin, Bing Xia   +9 more
wiley   +1 more source

Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies. [PDF]

Pharmaceuticals (Basel)
Niazi SK.
europepmc   +1 more source

Tobacco, the Food and Drug Administration, and Congress

, 2000
Leonard H. Glantz, George J. Annas
openalex   +2 more sources

Cholesterol in mRNA‐Lipid Nanoparticles can be Replaced with the Synthetic Mycobacterial Monomycoloyl Glycerol Analogue MMG‐1

Advanced Functional Materials, EarlyView.
This study demonstrates that cholesterol in messenger RNA‐lipid nanoparticles (mRNA‐LNPs) can be completely replaced with an immunopotentiating lipid, i.e., a synthetic analogue of the C‐type lectin receptor agonist monomycoloyl glycerol (MMG‐1), without compromising physicochemical properties, in vivo transfection efficiency, and immunogenicity of the
Abhijeet G. Lokras, Saahil S. Baghel, Rune F. Jensen, Aneesh Thakur, Henrik Franzyk, Oskar Thofte, Marco Herrera‐Barrera, Madeleine Landry, Melike Ongun, Ahmad Tami, Marlene P. Thanthrige, Eva Callens, Corinne Beinat, Thomas Rades, Søren R. Paludan, Kristian Riesbeck, Ida Rosenkrands, Dennis Christensen, Gabriel K. Pedersen, Camilla Foged   +19 more
wiley   +1 more source

A summary of Food and Drug Administration‐reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole [PDF]

, 2003
Joachim Labenz, Karl‐Uwe Petersen, Wolfgang Rösch, H. R. Koelz   +3 more
openalex   +1 more source

Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012–2018

Clinical pharmacology and therapy, 2020
Irin Tanaudommongkon, Shogo John Miyagi, D. Green, Janelle M. Burnham, J. Anker, Kyunghun Park, Johanna Wu, S. McCune, L. Yao, G. Burckart   +9 more
semanticscholar   +1 more source

Transducer Materials Mediated Deep Brain Stimulation in Neurological Disorders

Advanced Functional Materials, EarlyView.
This review discusses advanced transducer materials for improving deep brain stimulation (DBS) in neurological disorders. These materials respond to light, ultrasound, or magnetic fields, enabling precise, less invasive neuromodulation. Their stimulus‐responsive properties enhance neural control and adaptive therapy, paving the way for next‐generation ...
Di Zhao, Zhengyang Cao, Guangjun Zhong, Limin Shi, Junxia Xie, Jianhua Hao   +5 more
wiley   +1 more source